1Pili R, Donehower RC. ls HlF-1 alpha a valid therapeutic target[ J ]. J Natl Cancer lnst,2003,95 (7) :498499.
2Choi KS, Bae MK, Jeong JW, et al. Hypoxia-induced angiogenesis during carcinogenesis[J]. J Biochem Mol Biol,2003,36( 1 ) :120-127.
3Gregg L. Semenza H1F-1 and tumor progression: pathophysiology and therapeutics[J]. Trends Mol Med,2002,8(4) :S62-S67.
4Mazure NM, Brahimi-Hom MC, Pouyssegur J. Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis [ J ].Curt Pharm Des,2003,9(7) :531-541.
7Vincent KA, Feron O, Kelly RA. Harnessing the response to tissue hypoxia: H1F-1 alpha and therapeutic angiogenesis [J]. Trends Cardiovasc Med ,2002,12( 8 ) :362-367.
8Stadler W, Wilding G. Angiogenesis inhibitors in genitourinary cancers [ J ]. Crit Rev Oncol Hematol,2003,46 Supp1:41-47.
9Liu JY, Wei YQ, Yang L, et al. lmmunothempy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2 [J]. Blood,2003,15 : 1-7.
10Shinkaruk S,Bayle M, Lain G, et al. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy[ J ]. Curr Med Chem Anti-Canc Agents,2003,3 ( 2 ) :95 -117.
8Sluimer JC, Gasc JM, van Wanroij JL, et al. Hypoxia, hypoxiainducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis[J]. J Am Coll Cardial, 2008,51(13) : 1258-1265.
9Tal R, Shaish A, Bangio L, et al. Activation of C- transaetivation domain is essential for optimal HIF-1 alpha- mediated transcriptional and angiogenic effects[J]. Mierovasc Res,2008,76(1):1-6.
10Pugh CW,Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system[J]. Nat Med, 2003,9 (6) : 677-684.
